Skip to main content

Table 6 Total arsenic concentrations in HMW-F and LMW-F of PB and BM plasma collected during the remission induction therapy

From: Speciation of arsenic trioxide metabolites in peripheral blood and bone marrow from an acute promyelocytic leukemia patient

Clinical samples PB BM
Days after the start of administration -1 14 28 42 56 -1 14 28 42 56
Arsenic concentrations (ngAs/g) Total plasma 5.55 47.6 56.6 55.5 18.5 7.59 53.5 72.1 88.1 20.4
  HMW-F of plasma 1.31 20.1 25.0 27.7 9.98 1.77 26.3 44.2 62.9 14.4
  LMW-F of plasma 4.24 27.5 31.5 27.8 8.54 5.83 27.3 27.9 25.2 5.99
  1. PB and BM aspirations were collected before the treatment start (day -1), and 14, 28, 42, and 56 days after the start of administration. The total arsenic concentrations of HMW-F of PB and BM were determined by ICP-MS as described in "Patient and Methods". The total arsenic concentrations in LMW-F of PB and BM plasma were obtained by subtraction of that in HMW-F from the total arsenic concentrations in PB and BM plasma.